Search results
Results from the WOW.Com Content Network
Prior to the IPO, it had $62 million in cash and equivalents on its balance sheet. The IPO raised approximately $167 million. So, it should now have around $229 million in cash, a little over four ...
On Sept. 25, BioAge's stock proceeded with its IPO, which raised gross proceeds of $238.3 million. Before the IPO, it had raised $321 million via several rounds of funding with private investors ...
For premium support please call: 800-290-4726 more ways to reach us
Ginkgo Bioworks is an American biotech company founded in 2008 by five scientists from MIT, [3] headed by Jason Kelly. The company specializes in using genetic engineering to produce bacteria with industrial applications for other biotech companies, saving other companies the cost of reproducing the initial stages of design in synthetic biology.
Although no clinical development took place, Axovant held its IPO in June 2015 and raised $315 million, [4] the largest biotech IPO ever, [9] based on new phase IIB trials that were more promising. [10] The lock-up period against reselling stock was reduced to an unusually short 90 days for hedge funds that showed interest in the IPO. [11]
At the time, Acadia and Allergan were collaborating on development of a treatment for glaucoma, and Allergan would retain a 6.3% ownership stake in Acadia after the IPO. [20] However, the company's IPO, which ultimately took place in May 2004, [7] did not fare as well as expected and netted only US$35 million. [21]
Science & Tech. Shopping. Sports
Wake up with Breakfast news in your inbox every ... Joining Sonos in the Cloudy Outlook department is biotech company Maderna today. Shares down around 20%. ... at the time of the IPO, they said ...